TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19157139
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine group (Changpikang)
Study: 19157139
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (sulfasalazine)
Study: 19157139
Drug: Medicine and
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine and acupoint group (Changpikang and ear acupoint)
Study: 16176505
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two lactose tablets rectally)
Study: 12925933
Drug: Donepezil (acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (acetylcholinesterase inhibitor) for 12 weeks
Study: 10820860
Drug: Budesonide foam
Normalized name: budesonide Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide foam (1 mg/50 ml b.i.d.)
Study: 10820860
Drug: Mesalazine enemas
Normalized name: mesalamine Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine enemas (4 g/60 ml o.d.)
Study: 8875971
Drug: Fluvastatin 20-40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20-40 mg/day
Study: 8875971
Drug: Low-dose fluvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluvastatin plus niacin
Study: 8875971
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 or 40 mg/day
Study: 29290052
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of hydrocortisone
Study: 25406552
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy plus oral flunarizine
Study: 25406552
Drug: Oral flunarizine
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flunarizine alone
Study: 23098345
Drug: Prehospital aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital aspirin
Study: 23098345
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in recommended initial dose (160-325 mg)
Study: 16093252
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy plus 270 mg mebeverine taken thrice daily
Study: 12625151
Drug: Pyrantel-oxantel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel-oxantel (10 mg/kg)
Study: 12434648
Drug: Midodrine 10
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10 mg per os
Study: 7640495
Drug: Alcohol extraction
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol extraction of Abelmoschus manihot, Gliclazide and Captopril tablets
Study: 7640495
Drug: Gliclazide and
Normalized name: Gliclazide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide and Captopril tablets
Study: 2719459
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg orally
Study: 2719459
Drug: Amoxicillin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3.0 g plus probenecid 1.0 g orally
Study: 385458
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cimetidine per day
Study: 385458
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets containing lactose)
Study: 21086010
Drug: Training with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training with low level laser therapy (LLLT)
Study: 8151002
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patch
Study: 15514884
Drug: Profile preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profile preparation of the root canal with maillefer thermafil filling (Group A)
Study: 15514884
Drug: Profile preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profile preparation of the root canal with iodoform cataplasm and gutta percha filling (Group B)
Study: 15514884
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of the root canal with stainless steel hand-operated instruments, iodoform cataplasm and gutta percha filling (Group C)
Study: 9405581
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of [13C5] and [2H2]folic acid (approximately 500 nmol each)
Study: 9405581
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of [2H2]folic acid (226 nmol)
Study: 9405581
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of [13C5]folic acid (1010 nmol)
Study: 9405581
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of intravenous vs oral doses
Study: 8131770
Drug: TTS-NG (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS-NG (transdermal nitroglycerin) 10 mg.24 h-1
Study: 8131770
Drug: TTS-NG +
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS-NG + BNZ (benazepril 10 mg b.i.d.)
Study: 3314877
Drug: Control program
Normalized name: ZO Skin Health Pigment Control Program Plus Hydroquinone KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control program (no adjunct treatment)
Study: 31297739
Drug: Transcatheter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter treatment with MitraClip®
Study: 31297739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimal medical therapy)
Study: 27125909
Drug: Ubiquinol-10 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol-10 (150 mg/day)
Study: 12569288
Drug: Dacarbazine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (250 mg/m(2) days 1‐5 every 3 weeks) plus tamoxifen
Study: 12569288
Drug: Vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (3 mg/m(2) every week for 6 weeks, then every 2 weeks) plus tamoxifen
Study: 1352050
Drug: Remoxipride (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (150-300 mg daily)
Study: 6371649
Drug: Bichromatic argon
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bichromatic argon laser therapy (multiple wavelengths: 454.5 nm to 528.7 nm)
Study: 6371649
Drug: Monochromatic argon
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochromatic argon laser therapy (green wavelength at 514.5 nm)
Study: 6371649
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between bichromatic and monochromatic laser therapy
Study: 29126396
Drug: Structured, individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured, individualized endurance training and nutrition education based on the Mediterranean diet for 3 months, plus monthly group training and regular telephone contact during the subsequent 9 months
Study: 16513672
Drug: Intrabrachial infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrabrachial infusions of noradrenaline (NA)
Study: 16513672
Drug: Intrabrachial infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrabrachial infusions of tyramine (TYR)
Study: 12084809
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (2-2.5 mg patches/d)
Study: 2714912
Drug: oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral atenolol (100 mg per day)
Study: 2714912
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil (80 mg three times per day)
Study: 318849
Drug: Lignocaine, etidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine, etidocaine, and bupivacaine in 10-ml doses of plain solutions
Study: 31320738
Drug: ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab treatment
Study: 25439413
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg (Group O4)
Study: 25439413
Drug: ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 0.3 mg (Group R)
Study: 25439413
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg (Group O8)
Study: 11180025
Drug: Mizolastine 20
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 20 mg
Study: 10336575
Drug: Mizolastine 40
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 40 mg
Study: 2044648
Drug: Cholestyramine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (24 g daily in divided doses) plus moderate cholesterol-lowering diet
Study: 7006620
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg xipamide per day
Study: 7006620
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg xipamide per day
Study: 7006620
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of xipamide
Study: 22720051
Drug: Twice‐weekly, school‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐weekly, school‐based jumping regime
Study: 12455115
Drug: 1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ropivacaine without adrenalin but with 10 U/mL of hyaluronidase (Group RH)
Study: 8905242
Drug: Paracetamol 750
Normalized name: Hydrocodone bitartrate 7.5 mg and paracetamol 750 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 750 mg
Study: 8905242
Drug: Paracetamol 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1250 mg
Study: 8905242
Drug: Paracetamol 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1500 mg
Study: 1648944
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus infusion of metoclopramide (1 mg/kg, 30 min, every 8 h, day 1-5)
Study: 1648944
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of metoclopramide (3 mg/kg/24 h, 120 h)
Study: 1648944
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of metoclopramide
Study: 1648944
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus infusion of metoclopramide
Study: 31970581
Drug: Perceived drug-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived drug-related stigma measures
Study: 31970581
Drug: Internalized drug-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internalized drug-related stigma measures
Study: 31970581
Drug: Drug-related stigma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related stigma
Study: 29846653
Drug: EPA (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (2.7 g/d)
Study: 28131045
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (3 g/d)
Study: 24961021
Drug: 3% modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% modified fluid gel
Study: 22226431
Drug: Topical eflornithine
Normalized name: eflornithine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eflornithine hydrochloride
Study: 20074751
Drug: Endothelin‐A subtype
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin‐A subtype receptor antagonist sitaxsentan at 1 mg/kg
Study: 20074751
Drug: Endothelin‐A subtype
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin‐A subtype receptor antagonist sitaxsentan at 2 mg/kg
Study: 17684988
Drug: Agents containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents containing succinic and fumaric acids (Group 1, n = 11)
Study: 17684988
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy (Group 2, n = 11)
Study: 8499823
Drug: Amoxycillin once
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin once daily
Study: 31729550
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fentanyl infusion (1 mcg/kg/hr)
Study: 31729550
Drug: 24% oral
Normalized name: Entero VU, 24% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% oral sucrose (2 ml)
Study: 16182896
Drug: Single 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 20 mg/kg dose of ciprofloxacin
Study: 16182896
Drug: 12.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/kg of erythromycin every 6 h for 3 days
Study: 12468135
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E(2) and 0.5 mg NETA for 28 days
Study: 12468135
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE for 28 days and 5 mg MG for the final 14 days
Study: 12468135
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E(2) and 0.5 mg NETA
Study: 12840859
Drug: Control (natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (natural labor, no drug)
Study: 6763357
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg (Group A)
Study: 6763357
Drug: Albendazole 600
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 600 mg (Group B)
Study: 30794304
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg per day of DHA
Study: 24188512
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy for PTSD, 10 weekly sessions
Study: 23064072
Drug: Low-dose FP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FP chemotherapy (continuous 5-FU 500mg/day with intermittent CDDP 10mg/day)
Study: 23064072
Drug: Low-dose FP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FP chemotherapy (same regimen resumed after recurrence)
Study: 18634707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lactitol and Lactobacillus acidophilus NCFM, consumed twice daily for 2 weeks
Study: 18634707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lactitol and Lactobacillus acidophilus NCFM
Study: 17497139
Drug: High-dose venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose venlafaxine
Study: 17497139
Drug: High-dose sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sertraline
Study: 21838852
Drug: High-dose citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose citalopram
Study: 2205379
Drug: Intraperitoneal rIL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal rIL‐2 at 8 X 10(6) units/m2/dose
Study: 2205379
Drug: Intraperitoneal rIL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal rIL‐2 and LAK infusion
Study: 2205379
Drug: Intraperitoneal rIL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal rIL‐2 infusion
Study: 28242860
Drug: Sleep intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep intervention (sleep and combination)
Study: 28242860
Drug: FAB intervention
Normalized name: DIGOXIN IMMUNE FAB
DrugBank: Digoxin Immune Fab (Ovine) (DB00076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAB intervention (FAB and combination)
Study: 19158369
Drug: Fermagate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermagate 1 g three times daily
Study: 19158369
Drug: Fermagate 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermagate 2 g three times daily
Study: 17359569
Drug: Home health
Normalized name: SALICYLIC ACID 1.8 g in 100 mL TOPICAL SHAMPOO [Home Health Everclean Antidandruff]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home health care through a combination of traditional face‐to‐face and telemedicine visits (n = 83)
Study: 11491008
Drug: Mefloquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (10 mg/kg at 0 h, then 5 mg/kg at 6 h)
Study: 11491008
Drug: Artesunate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4 mg/kg on day 0, then 2 mg/kg on day 1 to 4)
Study: 7979523
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (40 mg/day)
Study: 7979523
Drug: Oxandrolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (2.5 mg/day)
Study: 3261651
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ungrafted arteries)
Study: 3261651
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (grafted arteries)
Study: 3261651
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (closed grafts)
Study: 3261651
Drug: Coronary artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary artery treatment (regardless of type)
Study: 31144431
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with dapagliflozin 5 mg/d plus saxagliptin 5 mg/d added to metformin
Study: 31144431
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with dapagliflozin added to metformin
Study: 31144431
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with saxagliptin added to metformin
Study: 31144431
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with dapagliflozin
Study: 31144431
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with saxagliptin
Study: 26656981
Drug: Integrative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative treatment including moxibustion therapy conducted twice a week for 4 weeks on bilateral acupoints SP6, LR3, and CV4.
Study: 26656981
Drug: Integrative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative treatment including moxibustion therapy.
Study: 26656981
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (watchful waiting or oral medication including α blocker, 5α-reductase inhibitors or antimuscarinic drugs).
Study: 11422959
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation on a weekly basis
Study: 11422959
Drug: Anthelmintic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelmintic treatment at the beginning and week 12
Study: 11422959
Drug: Both iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both iron supplementation and anthelmintic treatment
Study: 11422959
Drug: Lower haemoglobin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower haemoglobin values and anaemia (< 120 g/l Hb)
Study: 9050126
Drug: 10 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ng/ml haloperidol
Study: 3544626
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) combined with low-dose heparin (LDH)
Study: 28946789
Drug: Psychotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment for borderline personality disorder over four months
Study: 28946789
Drug: Individualized treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatments for personality disorders
Study: 24962666
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1,000 mg calcium per day and 50,000 U vitamin D3 pearl twice during the study)
Study: 21990519
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with stenting
Study: 21990519
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment without stenting
Study: 20113759
Drug: Interferential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential therapy with amplitude-modulated frequency (100Hz)
Study: 20113759
Drug: Interferential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential therapy without amplitude-modulated frequency (0Hz)
Study: 15957994
Drug: Intrapartum fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrapartum fentanyl (dose range 8-500 micrograms)
Study: 11912393
Drug: Capsaicin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (2 mM in 30 ml ethanol plus 70 ml 0.9% sodium chloride)
Study: 11912393
Drug: Resiniferatoxin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiniferatoxin (100 nM in 100 ml 0.9% sodium chloride)